146 related articles for article (PubMed ID: 25366056)
1. [Analytic and integrative perspectives for HIV vaccine design].
Yamamoto H
Uirusu; 2013; 63(2):219-32. PubMed ID: 25366056
[TBL] [Abstract][Full Text] [Related]
2. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
[TBL] [Abstract][Full Text] [Related]
3. [Theory for prophylactic AIDS vaccine development].
Nomura T; Matano T
Uirusu; 2009 Dec; 59(2):267-75. PubMed ID: 20218335
[TBL] [Abstract][Full Text] [Related]
4. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
5. Immunology and the elusive AIDS vaccine.
Virgin HW; Walker BD
Nature; 2010 Mar; 464(7286):224-31. PubMed ID: 20220841
[TBL] [Abstract][Full Text] [Related]
6. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
7. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.
Kawada M; Tsukamoto T; Yamamoto H; Takeda A; Igarashi H; Watkins DI; Matano T
J Virol; 2007 May; 81(10):5202-11. PubMed ID: 17344296
[TBL] [Abstract][Full Text] [Related]
8. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
[TBL] [Abstract][Full Text] [Related]
9. Development of prophylactic vaccines against HIV-1.
Schiffner T; Sattentau QJ; Dorrell L
Retrovirology; 2013 Jul; 10():72. PubMed ID: 23866844
[TBL] [Abstract][Full Text] [Related]
10. HIV-specific cytotoxic T lymphocytes and their possible implications in the future vaccine against AIDS.
Langlade-Demoyen P; Hoffenbach A
Res Immunol; 1989 Jan; 140(1):95-9; discussion 119-20. PubMed ID: 2567045
[No Abstract] [Full Text] [Related]
11. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
12. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the search for an HIV vaccine.
Lemckert AA; Goudsmit J; Barouch DH
Eur J Epidemiol; 2004; 19(6):513-6. PubMed ID: 15330122
[TBL] [Abstract][Full Text] [Related]
14. [Development of an AIDS vaccine: status report].
Girard MP
Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
[TBL] [Abstract][Full Text] [Related]
15. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
16. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.
Novitsky V; Rybak N; McLane MF; Gilbert P; Chigwedere P; Klein I; Gaolekwe S; Chang SY; Peter T; Thior I; Ndung'u T; Vannberg F; Foley BT; Marlink R; Lee TH; Essex M
J Virol; 2001 Oct; 75(19):9210-28. PubMed ID: 11533184
[TBL] [Abstract][Full Text] [Related]
17. Why can't the immune system control HIV-1? Defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity.
Ostrowski MA; Yu Q; Yue FY; Liu J; Jones B; Gu XX; Loutfy M; Kovacs CM; Halpenny R
Immunol Res; 2006; 35(1-2):89-102. PubMed ID: 17003512
[TBL] [Abstract][Full Text] [Related]
18. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Kundu SK; Katzenstein D; Moses LE; Merigan TC
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
[TBL] [Abstract][Full Text] [Related]
20. What are the correlates of protection?
Cohen J
Science; 1993 May; 260(5112):1259. PubMed ID: 8493565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
